Develops active bilayer films for high-oxygen-barrier packaging, suggesting a pathway for improved food preservation.
This study developed high-oxygen-barrier active bilayer packaging films by combining corona-treated low-density polyethylene (LDPE) with chitosan/glycerol (CS/Gl) and carvacrol@natural zeolite (CV@NZ) nanohybrid layers using industrially scalable processes. LDPE film was surface-activated via ambient-pressure corona treatment (0.75 s/cm2 at 45 kV, 30 W) and assembled with solution-cast CS/Gl or CS/Gl/CV@NZ monolayers via hot-pressing (110 °C, 1 min). Corona treatment enabled robust interfacial adhesion, evidenced by statistical equivalence between monolayer and bilayer mechanical properties. Incorporation of 10 wt.% CV@NZ nanohybrid increased elastic modulus by 60% (to ≈2970 MPa) and tensile strength by 30% (to ≈50 MPa). The LDPE-CS/Gl film achieved a 64-fold reduction in oxygen permeability; CV@NZ incorporation maintained excellent barrier performance (22-fold reduction). Antioxidant potency increased 16-fold upon CV@NZ incorporation. The LDPE-CS/Gl/CV@NZ film demonstrated exceptional antibacterial activity (5.08–5.30 log reductions; >99.999% kill) against both Listeria monocytogenes and Escherichia coli—substantially exceeding additive effects—confirming synergistic action between chitosan and carvacrol. In fresh minced pork preservation (8 days, 4 °C), the active film achieved a 1.73 log reduction in Total Viable Count (98.2% inhibition) and extended microbiological shelf life from 6 to beyond 8 days (33% increase). The bilayer configuration utilizes only 40% of the total thickness as biopolymer, aligning with circular economy principles. Unlike conventional high-barrier films (e.g., PA/PE) which require complex compatibilization for recycling, the water-soluble chitosan layer in this bilayer design can be readily separated from the LDPE backbone, enabling recovery of a pure polymer stream. This work demonstrates a feasible pathway for developing next-generation active packaging that combines a high oxygen barrier, potent antioxidant activity, and exceptional antimicrobial efficacy through industrially scalable manufacturing.
No takes yet. Share an insight, caveat, or question.
Leontiou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: